| 16.25 -0.025 (-0.15%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 19.31 | 1-year : | 22.56 |
| Resists | First : | 16.54 | Second : | 19.31 |
| Pivot price | 15.9  |
|||
| Supports | First : | 15.4 | Second : | 14.69 |
| MAs | MA(5) : | 16.24 |
MA(20) : | 15.84  |
| MA(100) : | 13.35 |
MA(250) : | 0 | |
| MACD | MACD : | 0.3 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 82.8 |
D(3) : | 84.7 |
| RSI | RSI(14): 62.6 |
|||
| 52-week | High : | 16.54 | Low : | 6.55 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AUPH ] has closed below upper band by 17.9%. Bollinger Bands are 52.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 16.36 - 16.45 | 16.45 - 16.51 |
| Low: | 15.93 - 16.02 | 16.02 - 16.09 |
| Close: | 16.12 - 16.26 | 16.26 - 16.37 |
Fri, 26 Dec 2025
Is Aurinia Pharmaceuticals (AUPH) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Thu, 25 Dec 2025
Aurinia Pharmaceuticals (NASDAQ:AUPH) rises 3.1% this week, taking three-year gains to 292% - simplywall.st
Mon, 22 Dec 2025
Aurinia Pharmaceuticals (NASDAQ:AUPH) Hits New 12-Month High - Here's Why - MarketBeat
Tue, 16 Dec 2025
Aurinia Pharmaceuticals: Silencing Doubters, But Competition Looms (NASDAQ:AUPH) - Seeking Alpha
Mon, 15 Dec 2025
Marex Group plc Buys Shares of 135,000 Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Thu, 11 Dec 2025
Aurinia Pharmaceuticals Inc $AUPH Shares Purchased by Jump Financial LLC - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 132 (M) |
| Shares Float | 128 (M) |
| Held by Insiders | 7.1 (%) |
| Held by Institutions | 50.7 (%) |
| Shares Short | 8,440 (K) |
| Shares Short P.Month | 8,320 (K) |
| EPS | 0.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.76 |
| Profit Margin | 29.2 % |
| Operating Margin | 40.4 % |
| Return on Assets (ttm) | 9.4 % |
| Return on Equity (ttm) | 20.6 % |
| Qtrly Rev. Growth | 8.3 % |
| Gross Profit (p.s.) | 1.61 |
| Sales Per Share | 2.01 |
| EBITDA (p.s.) | 0.76 |
| Qtrly Earnings Growth | 130 % |
| Operating Cash Flow | 120 (M) |
| Levered Free Cash Flow | 85 (M) |
| PE Ratio | 29.01 |
| PEG Ratio | 0 |
| Price to Book value | 5.86 |
| Price to Sales | 8.05 |
| Price to Cash Flow | 17.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|